title: [Intraoperative neurolysis of the celiac plexus in patients with unresectable pancreatic cancer].
abstract: BACKGROUND
  The analgetic treatment of inoperable pancreatic cancer patients is of paramount importance. The relative ineffectiveness of pharmacological agents has led many investigators to recommend chemical neurolysis of the celiac ganglions for pain control. However, the assessment of the results and the effectiveness of the block carried out during laparotomy have been unclear.
  
  
  METHODS
  After 41 intraoperative celiac neurolytic blocks pain intensity was retrospectively analysed in 38 patients suffering from unresectable pancreatic carcinoma. The mean age of the patients was 59 years, the observation period after neurolysis ranged to 6 months. All patients underwent definitive neurolysis using 50 % ethanol in 0.5 % prilocaine. Immediate and long-term efficacy, analgetic consumption and mortality were evaluated at follow-up. The calculated parenteral equivalent morphine dosage (mg per day) was evaluated before as well as at different time points after treatment as an objective parameter to describe pain intensity.
  
  
  RESULTS
  7 to 34 days (at discharge from the hospital) after block pain intensity was statistically highly significant reduced (p=0.016). Long-term results were obtained from 17 (10 to 12 weeks after intervention) and 9 (up to 20 weeks after intervention) patients respectively, demonstrating a long-lasting effect of the neurolysis. A statistical analysis was not possible because of the small patient 's number.
  
  
  CONCLUSIONS
  Intraoperative celiac neurolytic block is a safe and effective method of pain treatment in patients with unresectable pancreatic carcinoma. However, it alone provides complete pain relief until death only in a few cases. Therefore, it should be considered as an adjuvant treatment in the analgesic strategy. Combined palliative therapy is necessary in most of the cases.
authors.affiliation: Klinik für Anästhesiologie und Intensivtherapie am Wald-Klinikum Gera gGmbH. kai@waldklinikumgera.de
authors.forename: M
authors.initials: M
authors.lastname: Kretzschmar
authors.forename: J
authors.initials: J
authors.lastname: Krause
authors.forename: I
authors.initials: I
authors.lastname: Palutke
authors.forename: W
authors.initials: W
authors.lastname: Schirrmeister
authors.forename: H
authors.initials: H
authors.lastname: Schramm
mesh_terms: D000328:Adult; D000368:Aged; D015360:Analgesia, Epidural; D000700:Analgesics / Q000627:therapeutic use; D001340:Autonomic Nerve Block / Q000379:methods*; D002447:Celiac Plexus; D000431:Ethanol / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007430:Intraoperative Care; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000209:etiology; D059408:Pain Management; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D000700:Analgesics; D000431:Ethanol